CN1354660A - Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate - Google Patents
Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate Download PDFInfo
- Publication number
- CN1354660A CN1354660A CN99816756A CN99816756A CN1354660A CN 1354660 A CN1354660 A CN 1354660A CN 99816756 A CN99816756 A CN 99816756A CN 99816756 A CN99816756 A CN 99816756A CN 1354660 A CN1354660 A CN 1354660A
- Authority
- CN
- China
- Prior art keywords
- ranitidine
- preparation
- sucralfate
- coating
- alkali formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed is an orally administrable pharmaceutical preparation haivng therapeutic effect on gastrointestinal disorders which comprises as active ingredients ranitidine, bismuth subsitrate and sucralfate, wherein the ranitidine is coated with a coating agent to have a film dissolution time ranging from 20 to 90 minutes.
Description
Technical field
The present invention relates to comprise the pharmaceutical preparation of ranitidine, alkali formula bismuth citrate (bismuthsubcitrate) and sucralfate.More specifically, the present invention relates to the pharmaceutical preparation of novel Orally-administrable, it is by preventing when ranitidine, alkali formula bismuth citrate and sucralfate simultaneously during oral administration, the inhibitory action that ranitidine is absorbed by sucralfate and cause the reduction of therapeutic efficiency can reach the synergism of ranitidine, alkali formula bismuth citrate and sucralfate.Increase the absorbance of ranitidine according to the pharmaceutical preparation of Orally-administrable of the present invention, thereby the synergism by ranitidine, alkali formula bismuth citrate and sucralfate, the therapeutical effect that performance has significantly improved to gastric and duodenal ulcers.
Background technology
Gastrointestinal disorders is gastritis, gastric ulcer, duodenitis and duodenal ulcer for example, is caused by various factors.Recently, it is reported, gastrointestinal disorders is caused by the invasion and attack factor and defense factor imbalance, and the former is gastric acid, pepsin and helicobacter pylori (Helicobacter pylori) etc. for example, and the latter is for example from the regeneration activity of the excretory mucus of mucosa, tissue, the sanguimotor property improved.
In order to treat gastrointestinal disorders,, developed H so far as by medicine to the excretory inhibitory action treatment of invasion and attack factor gastric ulcer
2Antagonist, for example ranitidine, cimetidine and famotidine.But, known such medicine can not show lasting therapeutical effect, thereby gastrointestinal disorders often recurs (" U.S.'s internal medicine magazine " 91 rolled up (supplementary issue 2A) on August 8th, 1991).
Bismuth preparation is alkali formula bismuth citrate and basic bismuth salicylate for example, not only damages by strengthening defense factor protection gastric and duodenal ulcers when the treatment gastrointestinal disorders, and kills helicobacter pylori (" medicine " 36,132-157 (1988); " intestinal " 28,201-205 (1987); " american journal of gastroenterology " 84 volume 3 phases (1989)).But, known bismuth preparation can not show antiacid effect and the abirritation pain caused to gastric acid.
Sucralfate is when being used for the treatment of gastritis or gastric ulcer, and the pepsin of attacking the factor is served as in deactivation, stimulates the regeneration and the prostaglandin secretion of mucus secretion, antiacid effect, mucilage cell.But, known sucralfate can not participate in sour excretory inhibitory action.
Correspondingly, with H
2Antagonist combines administration with bismuth preparation be that the gastric ulcer Therapeutic Method of feature is disclosed among the European patent No.282132, with H
2Antagonist combines the method (" U.S.'s internal medicine magazine " 79 volume (supplementary issue 2c) on August 30th, 1985) openly in the literature that administration is a feature with sucralfate.But, the therapeutic effect to gastrointestinal disorders according to said method only is inadequate.
The inventor notices, gastrointestinal function should by the invasion and attack factor with the balance of defense factor normalization on the whole, not only in order to treat gastrointestinal disorders rapidly, gastric ulcer for example, and in order to reduce relapse rate.Found that, with H
2Ranitidine in the antagonist, the alkali formula bismuth citrate in the bismuth preparation and sucralfate can obtain the unexpected significant therapeutical effect (Korean Patent communique No.97-6083) to gastric and duodenal ulcers to rat administration simultaneously.
But, when ranitidine mixed with alkali formula bismuth citrate, the character of ranitidine was subjected to the appreciable impact of alkali formula bismuth citrate probably.Therefore,, ranitidine is made tablet according to any one conventional method, prepared tablet is carried out the film coating with hydroxypropyl emthylcellulose and glycerol, thereby make label in order to separate ranitidine and alkali formula bismuth citrate.Then, the label of film coating is mixed with alkali formula bismuth citrate and sucralfate, make the bilayer tablet that comprises label.
But, bilayer tablet in will being disclosed in Korean Patent communique No.97-6083 is during to patient's administration, because sucralfate absorption ranitidine causes the absorbance of ranitidine to reduce by 20 to 30%, they show not satisfied therapeutical effect to gastric ulcer, but they are to the excellent therapeutical effect of duodenal ulcer performance, just curative effect reach 90% or more than.
More specifically, alkali formula bismuth citrate and sucralfate directly show their effects to stomach, and after the inherent top of ranitidine body intestinal is absorbed,, show its therapeutical effect to gastrointestinal disorders by inhibitory action to gastric acid secretion along with blood circulation travels to stomach.
Particularly sucralfate is converted into sticky material in acidic gastric juice, is coated on the coat of the stomach then, thereby can protects coat of the stomach not to be subjected to the attack of the various invasion and attack factors.As mentioned above, sucralfate shows higher viscosity under acid condition, for example in gastric juice.Therefore, ranitidine causes ranitidine to be adsorbed by sucralfate with being used in combination of sucralfate, because the viscosity height of sucralfate.As a result, ranitidine no longer can travel to the top small intestinal, and the absorbance of ranitidine reduces by 20 to 30%, so it is reduced to 55 to 65% inevitably to the curative effect of gastric ulcer.
Disclosure of an invention
In order to solve as above problem, the inventor has carried out broad research, and purpose is by increasing the body internal absorption factor of ranitidine, improving the therapeutical effect of the pharmaceutical preparation of the Orally-administrable that comprises ranitidine, alkali formula bismuth citrate and sucralfate to gastrointestinal disorders.The result shockingly finds, if ranitidine is the film coating, wherein the dissolution time of film is longer than ranitidine and is travelled to the required time of top small intestinal from stomach, it is no longer adsorbed by sucralfate under one's belt so, can be absorbed after travelling to small intestinal, this treatment to gastrointestinal disorders is very effective, even to be mixed with under the various dosage form case of oral administration also be like this combining with alkali formula bismuth citrate and sucralfate, for example tablet, capsule or granule have finally been finished the present invention.
Correspondingly, the purpose of this invention is to provide the pharmaceutical preparation of the Orally-administrable that comprises ranitidine, alkali formula bismuth citrate and sucralfate, it is adsorbed and increases the absorbance of ranitidine by preventing ranitidine by sucralfate, to the excellent therapeutical effect of gastrointestinal disorders performance.
According to the present invention, when ranitidine combines oral administration with alkali formula bismuth citrate and sucralfate, it is not an eluting (elute) and being adsorbed by the high viscosity sucralfate under one's belt, but just eluting and disintegrate after travelling to the top small intestinal, thereby can be absorbed by height ratio in the body, thereby improve the curative effect of gastric ulcer.
The best mode that carries out an invention
Below will do to explain more specifically to the present invention.
The invention provides the pharmaceutical preparation of the Orally-administrable that comprises ranitidine, alkali formula bismuth citrate and sucralfate, might realize that ranitidine travels to the top small intestinal, be absorbed there, demonstration is to the inhibitory action of gastric secretion, and the disintegrate under one's belt immediately after administration of alkali formula bismuth citrate and sucralfate shows their therapeutical effect rapidly to gastrointestinal disorders.
According to the present invention, ranitidine is by being what to separate with the coating materials coating with alkali formula bismuth citrate and sucralfate, and purpose is not by the degeneration of alkali formula bismuth citrate, is not adsorbed by sucralfate and is absorbed by height ratio in small intestinal.More specifically, with ranitidine coating materials coating, the ranitidine with coating mixes with alkali formula bismuth citrate and sucralfate subsequently, makes the preparation of the Orally-administrable that contains ranitidine, alkali formula bismuth citrate and sucralfate by method of pharmacy.Preparation of the present invention after administration, alkali formula bismuth citrate and sucralfate eluting immediately under one's belt, ranitidine is exposed to gastric juice then.If the ranitidine of coating is eluting and disintegrate under one's belt before travelling to small intestinal, it is adsorbed by the high viscosity sucralfate so.Therefore, in order effectively to absorb in the body, importantly successfully do not travelled to small intestinal by eluting.As the various result of experiment of the present invention, when ranitidine during to empty stomach administration, it travelled to the top small intestinal in 20 to 30 minutes after in entering stomach, finished in 70 to 90 minutes after administration and passed the top small intestinal.
So ranitidine is through coating, the film dissolution time in acidic gastric juice is 20 to 90 minutes, and more preferably 30 to 70 minutes, purpose was not adsorbed by sucralfate under one's belt and be absorbed after travelling to small intestinal.
According to the present invention, be 20 to 90 minutes in order to adjust the film dissolution time of ranitidine in gastric juice, the ranitidine of film coating is placed in the beaker that contains 0.07M HCl, measure the film dissolution times down at 37 ℃.Measurement observes with the naked eye ranitidine institute elapsed time for the first time, as the film dissolution time along with the dissolving of film.
Pharmaceutical preparation according to the present invention is characterised in that ranitidine coating materials coating, making film dissolution time such as above-mentioned test evaluation is 20 to 90 minutes, this can prevent that ranitidine from adsorbing by the bismuth citrate degeneration of alkali formula with by sucralfate under one's belt, thereby increases the absorbance of ranitidine.
Among the present invention, in the coating machine of routine, for example Manesty Accela coating machine, Driam coating machine or Hi-coating machine, according to any one conventional method known in the art with ranitidine coating materials coating.Ranitidine behind the coating can be placed in the coating machine or transfer in drying oven or the high-temperature dryers dry.The coating materials that is used for the coating ranitidine must be at acidic gastric juice, be that 0.07M HCl had 20 minutes or above film dissolution time, perhaps must in alkalescence or neutral small intestinal, dissolve, and under acid condition, not dissolve.The representative example of this class coating materials is the enteric coating agent, hydroxypropylmethyl cellulose phthalate Eudragit L.S. for example, combine separately or with following: can be used in other cellulosic polymer in water solublity and the water-insoluble solvent system (for example based on the hydroxypropyl (hydroxypropoxy) and the methyl ether of cellulosic substrate, for example Sepifilm 002), can be used in the water-soluble solvent system alkylcellulose (for example methylcellulose, hydroxypropyl emthylcellulose) or can the film forming polymeric material of shape, for example Eudragit E..
Coating materials can contain excipient, is selected from plasticizer, for example propylene glycol, Myvacet, glycerol, Sorbitol, glycerol triacetate, diethyl phthalate or triethyl citrate; Antiseptic, for example methyl hydroxybenzoate or propyl ester; Coloring agent for example contains the titanium dioxide of crimson lake or ferrum oxide.These excipient help the coating operation, improve the shape of film.
Coating materials preferably can use 0.1 to 10.0 weight %, based on the weight of ranitidine.If less than 0.1 weight %, film dissolves in gastric juice so, ranitidine is eluting before travelling to small intestinal, by the absorption of thiosugar alcohol.If greater than 10.0 weight %, the dissolving of film will postpone so, and ranitidine passes the top small intestinal and eluting not, also not by little intestinal absorption.
According to the present invention, two kinds of methods are provided, be used for by ranitidine is prepared the dosage form of Orally-administrable with the coating materials coating.
According to a kind of method of the present invention, according to any one conventional method ranitidine is made granule, then granule is used the coating materials coating, obtain the film coated granules.Afterwards, with film coated granules and alkali formula bismuth citrate and sucralfate and one or more pharmaceutically acceptable carrier or mixed with excipients, obtain comprising granule, tablet or the capsule of the film coated granule of ranitidine.
According to another kind of method of the present invention, make the label that contains ranitidine according to any one conventional method, then label is used the coating materials coating, obtain containing the film coated cores of ranitidine.Afterwards, with label and alkali formula bismuth citrate and sucralfate and one or more the pharmaceutically acceptable carrier or the mixed with excipients of film coating, obtain comprising the bilayer tablet of label.
Granule, tablet, capsule and the bilayer tablet that comprises label can be prepared according to any one conventional method known in the art, and can comprise one or more pharmaceutically acceptable carrier or excipient, adhesive for example, for example pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl emthylcellulose, for example HPMC 5 or 6; Filler, for example starch, lactose, microcrystalline Cellulose or calcium phosphate; Disintegrating agent, for example potato starch, primojel, skim soybean extract, crospolyvinylpyrrolidone or cross-linked carboxymethyl cellulose; Lubricant or antiseize paste, for example hydrogenated vegetable oil, Talcum or silicon dioxide; Wetting agent, for example sodium lauryl sulfate.
Usually, gross weight based on preparation, the preparation of Orally-administrable of the present invention can comprise 1 to 2 weight portion ranitidine, 2 to 4 weight portion alkali formula bismuth citrates and 6 to 12 weight portion sucralfates, be preferably 50 to 300mg ranitidines, 100 to 400mg alkali formula bismuth citrates and 300 to 1200mg sucralfates, more preferably 50 to 150mg ranitidines, 100 to 200mg alkali formula bismuth citrates and 300 to 600mg sucralfates.
Preparation of the present invention preferably is administered once or twice every day, with 50 to 150mg ranitidines as unit dose.But, according to curee's reaction and/or according to the doctor's who leaves preparation prescription of the present invention evaluation, can increase and decrease unit dose.
The inventor be sure of, the preparation of described Orally-administrable can solve the problem that the absorbance of ranitidine is reduced by sucralfate fully, thereby the absorbance of raising ranitidine, by the synergism of ranitidine, alkali formula bismuth citrate and sucralfate the stomach obstacle is showed excellent therapeutical effect.
Embodiment
The following example will help to understand better the present invention.But, those skilled in the art will recognize easily that described concrete material and result only are illustrative, neither plan, also should not limit the present invention, and attached claims are described the present invention more fully.
Embodiment 1
Comprise the preparation of the granule of ranitidine coated granule
The preparation of A, ranitidine coated granule
1) the particulate preparation of ranitidine
The mixture that adds 84mg ranitidine hydrochloride (75mg ranitidine), 6mg microcrystalline Cellulose, 8mg carboxymethylcellulose calcium and 1mg hydroxypropyl cellulose in alcoholic solution is an amount of.The gained mixture of kneading, the mixture after will kneading is made granule according to conventional method.Afterwards, granule was divided into 20 order sifters and cross 32 order sifters.
2-1) film coating
The mixture that adds 4mg hydroxypropyl emthylcellulose, 1mg ethyl cellulose, 0.17mg glycerol in alcoholic solution is an amount of, makes the film coated composition.With 1) in the preparation granule carry out the film coating with the film coated composition according to conventional method, make the film coated granule of ranitidine.
2-2) enteric coating
In the distilled water solution of dichloromethane and isopropyl alcohol, add the mixture of 7.3mg hydroxypropylmethyl cellulose phthalate, 1.8mg purification Lac and 0.9mg Myvacet, make the enteric coating compositions.With 1) in the preparation granule carry out coating with this enteric coating compositions according to conventional method, make the full of enteric coated granules of ranitidine.
B, alkali formula bismuth citrate and the particulate preparation of sucralfate
The mixture that in distilled water, adds 300mg sucralfate, 100mg alkali formula bismuth citrate, 2.83mg microcrystalline Cellulose and 14mg hydroxypropyl cellulose, with the pelletize in high-speed mixer of whole mixture, with the mixture drying after the pelletize, make the granule that comprises sucralfate and alkali formula bismuth citrate.
C, comprise the preparation of the granule of ranitidine coated granule
With the granule and 1 for preparing among the B) in the preparation 104.17mg film coating or the ranitidine granule (75mg ranitidine) of enteric coating mix, obtain comprising the granule of ranitidine coated granule.
Embodiment 2
Comprise the preparation of the capsule of ranitidine coated granule
The 521mg granule of preparation among the embodiment 1 is filled in the capsule according to conventional method, thereby makes the capsule that comprises the ranitidine coated granule.
Embodiment 3
Comprise the preparation of the tablet of ranitidine coated granule
The mixture of film coated granule (75mg ranitidine), 300mg sucralfate, 100mg alkali formula bismuth citrate, 53.83mg microcrystalline Cellulose, 30mg lactose, 10mg carboxymethyl cellulose and the 2mg magnesium stearate of the 104.17mg ranitidine of use embodiment 1A preparation is made the 600mg tablet according to conventional method.
Embodiment 4
Comprise the preparation of the bilayer tablet of ranitidine coated cores
The preparation of A, ranitidine coated cores
1) preparation of ranitidine label
84mg ranitidine hydrochloride (75mg ranitidine), 6mg microcrystalline Cellulose are mixed with the 1mg hydroxypropyl cellulose, in alcoholic solution, add this mixture.According to conventional method with whole mixture knead, pelletize.With the mixture drying after the pelletize, sieve.Granule is mixed with 8mg carboxymethyl cellulose and 2mg magnesium stearate, whole mixture are pressed into the ranitidine label.
2-1) film coating
In alcoholic solution, add the mixture of 3mg hydroxypropyl emthylcellulose, 1mg ethyl cellulose, 0.8mg titanium dioxide, 0.4mg Talcum and 0.2mg Polyethylene Glycol, make the film coated composition.With 1) in the preparation the ranitidine label carry out coating with coated composition according to conventional method, make the film coated cores of ranitidine.
2-2) enteric coating
In acetone and alcoholic acid solution, add the mixture of 7.2mg hydroxypropylmethyl cellulose phthalate and 0.8mg Myvacet, make the enteric coating compositions.With 1) in the preparation the ranitidine label carry out coating with this coated composition according to conventional method, make the enteric coating label of ranitidine.
B, alkali formula bismuth citrate and the particulate preparation of sucralfate
The mixture that in alcoholic solution, adds 300mg sucralfate, 100mg alkali formula bismuth citrate, 86.46mg microcrystalline Cellulose and 20mg hydroxypropyl cellulose.Whole mixture of kneading, the mixture after will kneading is then made the granule of sucralfate and alkali formula bismuth citrate according to conventional method pelletize, drying.
C, comprise the preparation of the bilayer tablet of ranitidine label
The alkali formula bismuth citrate for preparing among the B and the granule of sucralfate are mixed with 20mg carboxymethylcellulose calcium and 4mg magnesium stearate.The film coating or the enteric coating label of gained mixture and 106.4mg ranitidine hydrochloride (75mg ranitidine) are made the bilayer tablet that comprises label according to conventional method.
D, coating
In alcoholic solution, add the mixture of 6.5mg hydroxypropyl emthylcellulose, 1.7mg titanium dioxide, 0.9mg Talcum and 0.34mg Polyethylene Glycol, make the film coated composition.The bilayer tablet for preparing among the C is carried out the film coating with the film coated composition, obtain the bilayer tablet of film coating.
Comparative Examples
Comprise the preparation of the bilayer tablet of ranitidine label
According to Korean Patent communique No.97-6083 preparation example 4 disclosed methods, use the mixture of 84mg ranitidine hydrochloride (75mg ranitidine), 300mg sucralfate, 100mg alkali formula bismuth citrate, 3.5mg microcrystalline Cellulose, 14.0mg hydroxypropyl emthylcellulose, 17mg carboxymethyl cellulose, 11mg magnesium stearate, 14.5mg hydroxypropyl emthylcellulose, 5.1mg glycerol and 0.9mg titanium dioxide, preparation comprises the bilayer tablet of ranitidine label.
Test example 1
In acidity is the measurement of the film dissolution time in the gastric juice of 0.07M HCl
The film dissolution time of the bilayer tablet for preparing in following measurement embodiment 4 and the Comparative Examples.
In beaker, contain 37 ℃ 0.07M hydrochloric acid solution, to wherein adding the bilayer tablet for preparing in embodiment 4 and the Comparative Examples respectively.Afterwards, measure the film dissolving respectively and observe with the naked eye ranitidine institute elapsed time, evaluated for film dissolution time for the first time.The result is as shown in table 1 below.
Table 1: in acidity is film dissolution time (10) in the gastric juice of 0.07M HCl
| For test piece | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Embodiment 6 | 34.5 | 38.8 | 35.1 | 37.3 | 36.4 | 35.3 | 37.9 | 34.8 | 39.2 | 38.5 |
| Comparative Examples | 6.2 | 6.8 | 7.4 | 7.8 | 6.1 | 6.6 | 7.2 | 6.3 | 7.5 | 6.7 |
As above shown in the table 1, the film dissolution time of the bilayer tablet of preparation is longer than 30 minutes among the embodiment 4, and the film of the bilayer tablet for preparing in the Comparative Examples dissolves rapidly, and their film dissolution time is shorter than 8 minutes.
Test example 2
The measurement of the ranitidine body internal absorption factor of oral administration
In order to identify that whether preparation according to the present invention suppresses the absorption of ranitidine to the human body administration, measures 18 25 to 30 years old healthy people's ranitidine haemoconcentration through certain hour.The results are shown in the following table 2.
Table 2: ranitidine haemoconcentration and pharmacokinetic parameters behind the human body oral administration are changed
| For test preparation | Curee's quantity | ?AUC(ng/hr/ml) | ??C max(ng/ml) | ???T max(hr) |
| Embodiment 1 | ????6 | ??2285±115.2* | 485.3±30.6* | ??2.86±0.29 |
| Embodiment 4 | ????6 | ??2354±103.5* | 493.4±31.2* | ??2.69±0.35 |
| Comparative Examples | ????6 | ??1623±98.6 | 293.7±34.6 | ??3.23±0.41 |
*: the significance level of the relative Comparative Examples of bilayer tablet; P＜0.05
As above shown in the table 2, compare, significantly increased AUC and maximum haemoconcentration (C according to bilayer tablet of the present invention with preparation according to Comparative Examples
Max).Therefore, ranitidine is expected at according to effectively being absorbed after the preparation administration of the present invention.
Test example 3
The interior therapeutical effect of body to gastric ulcer
In order to estimate the therapeutical effect of preparation of the present invention to gastric ulcer, to suffering from 20 to 50 years old six week of volunteer's oral administration of gastric ulcer, the ulcer diameter is 10 to 25mm with the granule of preparation among the embodiment 1.Determine the gastric ulcer recovery from illness by splanchnoscopy.The result is as shown in table 3 below.
Table 3: to the therapeutical effect of human stomach ulcer
| For test preparation | Curee's quantity | Curee's quantity of recovery from illness | Curative effect (%) |
| Embodiment 1 | ????????5 | ??????????4 | ????80 |
| Embodiment 4 | ????????5 | ??????????5 | ????100 |
| Comparative Examples | ????????5 | ??????????3 | ????60 |
As above shown in the table 3, compare with the bilayer tablet of Comparative Examples, bilayer tablet of the present invention and granule significantly improve the therapeutic effect to gastric ulcer.
From test example 1 to 3 result as can be seen, the pharmaceutical preparation of Orally-administrable of the present invention comprises ranitidine, alkali formula bismuth citrate and sucralfate, ranitidine coating materials coating wherein, film dissolution time with 20 to 90 minutes, said preparation is to the excellent therapeutical effect of gastrointestinal disorders performance, solved prior art problems fully, just ranitidine can not effectively be absorbed in the body because of being adsorbed by sucralfate under one's belt.So according to the present invention, the synergism by ranitidine, alkali formula bismuth citrate and sucralfate can obtain unexpected significantly to the therapeutical effect of gastric ulcer.
Claims (8)
1, the pharmaceutical preparation that gastrointestinal disorders is had the Orally-administrable of therapeutical effect comprises ranitidine, alkali formula bismuth citrate and sucralfate as active component, ranitidine coating materials coating wherein, thus have 20 to 90 minutes film dissolution time.
2, according to the preparation of claim 1, wherein the film dissolution time is 30 to 70 minutes.
3, according to the preparation of claim 1, wherein ranitidine is with 0.1-10.0 weight % coating materials coating, based on the weight of ranitidine.
4, according to the preparation of claim 3, wherein this coating materials is selected from the group of being made up of hydroxypropyl emthylcellulose, methylcellulose and Eudragit.
5, according to the preparation of claim 3, wherein this coating materials is a kind of enteric coating agent.
6, according to the preparation of claim 5, wherein this enteric coating agent is hydroxypropylmethyl cellulose phthalate or Eudragit E.S..
7, according to the preparation of claim 1, wherein said preparation is made granule, capsule, tablet by method of pharmacy or is comprised the bilayer tablet of coated cores.
8, according to the preparation of claim 7, wherein this coated cores is preparation like this: with ranitidine and pharmaceutically acceptable carrier or mixed with excipients, make label, and with label coating materials coating.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR1999/000327 WO2000078307A1 (en) | 1999-06-21 | 1999-06-21 | Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1354660A true CN1354660A (en) | 2002-06-19 |
| CN1173698C CN1173698C (en) | 2004-11-03 |
Family
ID=19570891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB998167568A Expired - Lifetime CN1173698C (en) | 1999-06-21 | 1999-06-21 | Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR100453179B1 (en) |
| CN (1) | CN1173698C (en) |
| AU (1) | AU4655199A (en) |
| WO (1) | WO2000078307A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507717B (en) * | 2009-03-13 | 2013-01-23 | 沈阳药科大学 | Composite tablet capable of treating peptic ulcer and preparation method thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006103702A2 (en) * | 2005-04-01 | 2006-10-05 | Mccullough Ricky W | Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium |
| CN101607086B (en) * | 2009-07-21 | 2011-11-02 | 山西安特生物制药股份有限公司 | Compound bismuth composition and preparation method thereof |
| KR101583452B1 (en) | 2015-01-30 | 2016-01-11 | 주식회사 대웅제약 | A pharmaceutical composition for treating gastrointestinal diseases |
| KR101801064B1 (en) | 2015-07-20 | 2017-11-27 | 안국약품 주식회사 | Three-layered tablet for treating stomach and intestines disease |
| KR101794529B1 (en) * | 2016-06-14 | 2017-11-07 | 주식회사 인트로바이오파마 | Film-coated tablet for gastrointestinal disease, and method of preparing the same |
| KR20230156474A (en) | 2022-05-06 | 2023-11-14 | 에니솔루션 주식회사 | Composite tablet for treating stomach and intestines disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0403048A3 (en) * | 1989-06-14 | 1991-01-30 | Warner-Lambert Company | Medicated compositions containing sucralfate and processes for their production |
| JP3677376B2 (en) * | 1996-08-13 | 2005-07-27 | 武田薬品工業株式会社 | Medicine |
-
1999
- 1999-06-21 AU AU46551/99A patent/AU4655199A/en not_active Abandoned
- 1999-06-21 WO PCT/KR1999/000327 patent/WO2000078307A1/en active IP Right Grant
- 1999-06-21 CN CNB998167568A patent/CN1173698C/en not_active Expired - Lifetime
- 1999-06-21 KR KR10-2001-7016389A patent/KR100453179B1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507717B (en) * | 2009-03-13 | 2013-01-23 | 沈阳药科大学 | Composite tablet capable of treating peptic ulcer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020031342A (en) | 2002-05-01 |
| WO2000078307A1 (en) | 2000-12-28 |
| KR100453179B1 (en) | 2004-10-15 |
| AU4655199A (en) | 2001-01-09 |
| CN1173698C (en) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2179453C2 (en) | Peroral pharmaceutical medicinal forms including proton pump inhibitor and antacid substance or alginate | |
| CN1131027C (en) | Controlled release formulation for poorly soluble basic drugs | |
| EP2493456B1 (en) | Solid dispersion of rifaximin | |
| CN111093653B (en) | Deuterated domperidone compositions, methods and preparations | |
| CN1348384A (en) | An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport | |
| CN1911250A (en) | Traditional Chinese medicine enteric oral liquor using leech extractive as active component, and its preparation method | |
| US20070160664A1 (en) | Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent | |
| US20200297640A1 (en) | Orally administrable compositions comprising calcium | |
| AU2009256423A1 (en) | Pulsatile release of valsartan | |
| CN109893516A (en) | For treating the pharmaceutical composition of helicobacter pylori | |
| CN1173698C (en) | Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate | |
| CN1538837A (en) | Swallow tablet comprising paracetamol | |
| US20080038336A1 (en) | Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent | |
| CN115209910A (en) | Oral pharmaceutical composition | |
| CN101057861B (en) | Polycarbophil enteric coated medicinal composition | |
| CN112618505B (en) | Compound pharmaceutical composition containing benazepril and pimobendan for pets and preparation method thereof | |
| CN1759830A (en) | Enteric coated table of duloxetine, and preparation method | |
| CN1080851A (en) | The reinforcing agent of somatostatin | |
| CN1736378A (en) | Injection with omeprazole and domperidone | |
| KR20060117752A (en) | Pharmaceutical compositions containing lipase inhibitor | |
| CN1440278A (en) | Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethy lene) cytidine | |
| CN1305379A (en) | Method of treatment | |
| US20170326065A1 (en) | Methods and composition for treatment of cardiovascular conditions | |
| CN1872061A (en) | Soft capsule of medication composition, and preparation method | |
| CN1634082A (en) | Enteric coated orally disintegrating tablet of aspirin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20041103 |